Leukaemia differentiation therapy using Mogrify
exploratoryresearch program · medium · Fri Oct 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Use the Mogrify algorithm to identify transcription factors and drug combinations that induce differentiation in acute promyelocytic leukaemia cells.
Network pharmacology approach combining Mogrify-identified transcription factor regulatory networks with Connectivity Map analysis and pharmacological testing of candidate drugs.
Oncogene publication in 2022 reported proof-of-concept results using Mogrify for leukaemia differentiation therapy.
ATRA was recovered as the top hit; dimaprit and mebendazole were identified as a drug combination that induces myeloid differentiation; manipulation or pharmacological targeting of MYC and IRF1 induced APL differentiation and effects were also shown in primary patient-derived APL cells.
Diabetes in vivo reprogramming program
preclinicaldrug program · medium
Restore lost cell types and organ function in diabetes through direct in situ cellular reprogramming.
In vivo reprogramming therapy based on factors identified by MOGRIFY and epiMOGRIFY platforms.
Series A funding total of £35 million GBP ($46 million USD) was stated to support selection and advancement of in vivo reprogramming concepts including diabetes.
epiMOGRIFY platform
exploratoryplatform · high
Identify factors that can maintain or establish cell identity for therapeutic cellular reprogramming applications.
Computational cell-identity platform using transcriptomic, epigenetic, sequencing, and regulatory data.
epiMOGRIFY cell identity platform and validation listed as a 2020 site-mentioned publication/program output.
The supplied material states that epiMOGRIFY was validated, but does not provide detailed validation results.
MOGRIFY platform
exploratoryplatform · high
Identify transcription factors and regulatory networks capable of converting one cell type into another for direct cellular reprogramming applications.
Computational platform using transcriptomic, gene regulatory, sequencing, and molecular interaction network data to rank transcription factors for cell conversion.
MOGRIFY V1 platform and cell conversion results listed as a 2016 site-mentioned publication/program output.
The supplied material states that MOGRIFY V1 produced cell conversion results, but does not provide detailed outcomes.
Ophthalmology in vivo reprogramming program
preclinicaldrug program · medium
Restore lost cell types and organ function in ophthalmology indications through direct in situ cellular reprogramming.
In vivo reprogramming therapy based on factors identified by MOGRIFY and epiMOGRIFY platforms.
Series A funding total of £35 million GBP ($46 million USD) was stated to support selection and advancement of in vivo reprogramming concepts including ophthalmology.
Otology in vivo reprogramming program
preclinicaldrug program · medium
Restore lost cell types and organ function in otology indications through direct in situ cellular reprogramming.
In vivo reprogramming therapy based on factors identified by MOGRIFY and epiMOGRIFY platforms.
Series A funding total of £35 million GBP ($46 million USD) was stated to support selection and advancement of in vivo reprogramming concepts including otology.
